China CAS:57-83-0 Manufacturer

We are commitment to offer the competitive price ,outstanding products quality, as well as fast delivery for CAS:57-83-0, With our rules of " small business track record, partner trust and mutual benefit", welcome all of you to definitely work together , expand with each other.
CAS:57-83-0, Our aim is to help customers realize their goals. We have been making great efforts to achieve this win-win situation and sincerely welcome you to join us. In a word, when you choose us, you choose a perfect life. Welcome to visit our factory and welcome your order! For further inquiries, remember to do not hesitate to contact us.

Hot Products

  • Tibolone

    Tibolone

    Tibolone complies with EP specification. DMF is approved.

    CAS:5630-53-5

  • Drospirenone

    Drospirenone

    Drospirenone has EP,USP specifications. DMF approved.

    CAS:67392-87-4

  • Ganciclovir

    Ganciclovir

    Ganciclovir has CP ,EP, USP specification. DMF and GMP approved.

    CAS:82410-32-0

  • 21-acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione

    21-acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione

    21-Acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione is an intermediate in the synthesis of Budesonide (B689490) related derivatives.

    CAS:3044-42-6

  • Mifepristone Tablets

    Mifepristone Tablets

    Mifepristone Tablets Specifications:10mg*1
    Indications:Emergency Contraceptive
  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept